Zadaxin Explored for Immune Reconstitution in HIV-Positive Patients

For individuals living with HIV-1 infection, immune reconstitution disorders remain a significant challenge, often leading to persistent immune dysfunction despite antiretroviral therapy. Thymosin α-1 (Tα1), marketed as Zadaxin®, has previously shown promise as an immune adjuvant in HIV-1 patients, demonstrating synergistic effects with Interferon-α (IFN-α) to enhance immunity. Prior research also indicated that a triple combination of Tα1, IFN-α, and Zidovudine improved tolerability, safety, and efficacy, leading to lower HIV RNA and more stable CD4+ T cell counts. This study aimed to specifically evaluate Zadaxin's safety and efficacy in HIV-positive patients experiencing immune reconstitution disorders, a population where targeted immune support is crucial.

While the abstract describes the study's purpose and hypothesis rather than its definitive results, the researchers aimed to confirm several key benefits observed in prior investigations. Previous studies using Thymosin α-1 (Tα1) as an immune adjuvant in HIV-1 patients, particularly in combination with Interferon-α (IFN-α) and Zidovudine, demonstrated a synergistic effect leading to lower HIV RNA and more stable high CD4+ T cell counts. The current study hypothesized that Zadaxin® would similarly improve immune reconstitution in HIV-positive patients. Specifically, they anticipated an increase in CD4+ T cell count, a reduction in viral load, and an overall improvement in safety profile. The primary aim was to evaluate if Zadaxin® could significantly increase CD4+ T cell counts and reduce viral load in patients with immune reconstitution disorders, building on evidence of its ability to promote immune reconstitution in thymectomized mice.